BioCentury
ARTICLE | Company News

Wyeth in trio of deals

February 6, 2007 3:13 AM UTC

WYE was involved in three deals announced on Monday, one focusing on schizophrenia and two for hemophilia B. The pharma received rights from elbion (Leuven, Belgium) to develop and commercialize preclinical phosphodiesterase-10 (PDE-10) inhibitors to treat schizophrenia. elbion will receive an undisclosed upfront payment and research funding and is eligible for milestones, all of which could total $110 million, plus royalties.

WYE also partnered with Nautilus (Paris, France) to discover and develop recombinant Factor IX proteins for hemophilia B. Nautilus will use its protein engineering technology to improve the duration of action of recombinant Factor IX compounds, while WYE will develop, manufacture and commercialize compounds resulting from the collaboration. Nautilus will receive an undisclosed upfront payment and R&D funding, and is eligible for milestones, plus royalties. ...